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Abstract
Background: Ghrelin is a potent hormone with central and peripheral action. This hormone plays an important role in the regulation of appetite, food intake, 
and energy balance. Studies have suggested that ghrelin is involved with eating disorders (ED), particularly bingeing and purging. Genetic variants have also 
been studied to explain changes in eating behavior. Methods: We conducted a literature review; we searched PubMed, Scientific Electronic Library Online 
(SciELO), and LILACS databases using the keywords “eating disorder”, “ghrelin”, “polymorphism”, “anorexia nervosa”, “bulimia nervosa”, “binge eating disor-
der”, and their combinations. We found 319 articles. Thirty-nine articles met the inclusion criteria. Results: High levels of ghrelin were found in patients with 
anorexia nervosa (AN), especially in the purging subtype (AN-P). There was also a positive correlation between fasting ghrelin level and frequency of episodes 
of bingeing/purging in bulimia nervosa (BN) and the frequency of bingeing in periodic binge eating disorder (BED). Some polymorphisms were associated 
with AN and BN. Conclusion: Changes in ghrelin levels and its polymorphism may be involved in the pathogenesis of EDs; however, further studies should 
be conducted to clarify the associations.
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Introduction
Eating disorders (ED) are characterized by severe changes in eat-
ing behavior1-3. Anorexia nervosa (AN), bulimia nervosa (BN) and 
binge eating disorder (BED) are EDs known for their high mor-
bidity and mortality affecting mostly adolescents and young adult 
females and can lead to major biological, psychological and social 
complications4-7. AN is characterized by intense fear of weight gain, 
severe food restriction, low body weight and a distorted perception 
of the body image. BN is characterized by episodes of binge eating 
(uncontrolled consumption of a large amount of food in a short 
period of time) followed by inappropriate compensatory behaviors 
aimed at preventing weight gain (such as: self-induced vomiting, 
abuse of laxatives, diuretics, amphetamines and/or excessive physical 
activity), these episodes must occur at least once per week for three 
months. Finally, BED is characterized by episodes of binge eating as 
described previously but without the use of compensatory methods, 
as frequently quoted in BN2,6.
Studies indicate a prevalence of ED ranging from 0.4% to 1.6%, 
with the highest frequency found in young women (between 18 and 
32 years old)2,4. In Brazil, there is still a scarce number of epidemio-
logical studies involving ED, even if the number of these studies has 
increased in recent years8.
The etiology of an ED is complex and although widely studied, is 
still poorly understood. It is believed that the disease is multifactorial 
with a complex interaction of several factors: biological, psychologi-
cal, sociocultural and family-related which are responsible for initiat-
ing and maintaining ED9-11. There is substantial evidence that genetic 
factors have up to an 80% stake in the etiology of AN12, however, little 
is known about the molecular mechanism of these cases13.
Most genetic studies on ED are focused on the investigation of 
candidate genes. Several genes that play an important role in appetite 
regulation and satiety are considered candidates and may be related 
to the development of ED14-18, but the results of these studies are still 
inconsistent19,20.
One of the major hormones involved in the regulation of food 
intake is ghrelin. Although there are many neuropeptides that stimu-
late food intake, ghrelin is the most established orexigenic peptide 
known until now21.
Methods 
We conducted a literature review to human studies in PubMed, 
Scientific Electronic Library Online (SciELO) and Lilacs databases, 
published between January 2000 and December 2014. The main 
keywords were used: “eating disorder” and “ghrelin”, and filtered the 
results to the terms: “anorexia nervosa”, “bulimia nervosa”, “binge 
eating disorder”, “polymorphism” and their combinations. The inclu-
sion criteria were: 1) articles in English, Portuguese and Spanish; 2) 
articles that fully approached the topic ghrelin, eating disorders and 
their possible biological/genetic changes; 3) only studies in patients 
with diagnoses AN, BN and BED. 
Three hundred and nineteen articles were found and only 39 
contemplated these criteria (5 review articles, meta-analysis 1 and 
33 experimental articles). Review articles and meta-analysis on the 
subject were consulted and cited in the discussion of this review, 
but for the presentation of data only original articles were used. We 
excluded studies in other languages and case reports as well, as articles 
that exclusively broached the topic obesity and ghrelin.
Results
The synthesis of these studies is presented in tables 1 and 2, sorted 
by month and year of publication. All data were taken from the 
original articles. To facilitate comparison we standardized the dis-
play of age and BMI and consider only one house after the comma 
without rounding.
Ghrelin and the regulation of appetite
The arcuate nucleus (ARC) of the hypothalmus and the brain stem 
are important regions involved in the regulation of appetite, body 
weight and energy balance22. The variety of hypothalamic appetite 
regulators are divided into two groups: The orexigenic types (ap-
petite stimulators) which include the neuropeptide Y (NPY), the 
agouti-related peptide (AgRP), ghrelin, orexin and cannabinoids, 
while the anorectics (appetite suppressants) which include pro-
opiomelanocortin (POMC), and cocaine and amphetamine regulated 
transcript (CART), thyrotropin releasing hormone (TRH), cortico-
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tropin releasing hormone (CRH), peptide YY (PYY), cholecystokinin 
(CCK) and glucagon-like-peptide (GLP 1), among other23.
Ghrelin is a peptide of 28 amino acids, synthesized mainly by 
the oxyntic glands of the stomach24. It is acylated in the third residue 
which is a serine, the introduction of fatty acid (n-octanoyl) is es-
sential for its activity25.
It is one of the major signaling mechanisms for the start of the 
meal26. In humans, its concentration stays high during periods of 
fasting and periods that precede meals, falling soon after the start 
of food intake27,28.
It is also involved in stimulating the secretion of growth hormone 
(GH) via the endogenous ligand of the GH secretagogue receptor 
(GHS-R)29. There are two subtypes of receptors, GHS-R1a, which is 
active, and GHS-R1b, a smaller isoform, which apparently has no 
biological activity30. This receptor (GHS-R) is present in various tis-
sues including the anterior hypophysis and the hypothalamus, and in 
other areas of the brain, such as the hippocampus and gray matter. 
Because of its location, it has been suggested that GHS-R can modu-
late biological rhythms, mood, memory, learning and appetite31.
Ghrelin is an orexigenic hormone that acts on the Central Ner-
vous System (CNS) by activating the NPY/AgRP32 neurons in the 
ARC via the GHS-R receptor. Thus, it promotes the production and 
secretion of other orexigenic neuropeptides that suppress neuronal 
activity of the POMC/CART, while stimulating food intake33, this 
hormone undergoes a process of acetylation required to bypass the 
blood-brain barrier, making it suitable to connect to the GHS-R1a34. 
This acetylation converts the desacyl ghrelin (inactive form) into 
acyl ghrelin (active form)35 and is catalyzed by the enzyme ghrelin 
O-acyltransferase (GOAT)25 (Figure 1).
to have an inverse correlation with the body mass index (BMI)28,36. 
Studies have shown that ghrelin levels are lower in obese subjects as 
compared to control subjects36-39. One study noted that the decrease 
in ghrelin after the meal was lower in obese individuals compared to 
normal weight individuals40, and can thereby maintain the feeling of 
hunger. Studies with obese children also found low plasma ghrelin 
levels41,42 and when these children have reduced 50% of their BMI, 
ghrelin levels remained lower in comparison to control subjects41. 
The same finding was observed in obese adults who normalized 
their BMI43,44.
Studies conducted with AN patients found high levels of ghre-
lin in the plasma of these patients when compared with control of 
normal-weight individuals39,45-49 which may suggest that this change 
may be an adaptive response to prolonged starvation50. Tolle et al. 
compared the levels of ghrelin plasma in 3 groups: healthy women 
considered thin (CT), who had a BMI similar to women with AN; 
patients with AN and women with normal weight (NW)51. It was 
demonstrated that ghrelin plasma concentrations in fasting patients 
with AN, was increased and remained high throughout the day 
(measured every 4 hours over a period of 24 hours) as compared 
to CT and NW. The study noted that these levels normalized after 
the patient gained the weight back, suggesting that in addition to 
body weight, levels of ghrelin may also be affected by the nutritional 
state51. Body fat instead of BMI has best explained the changes in the 
levels of ghrelin47, some of the groups that had contradictory results 
between the correlation of BMI and ghrelin showed consistent results 
for body fat37,45,52-54. Studies have shown that ghrelin levels in patients 
with AN Restrictive (AN-R) have not been fully standardized, even 
after treatment41,55-58.
Differences in ghrelin levels between subtypes of AN have also 
been reported. Tanaka et al. in 2003 found higher plasma levels of 
ghrelin in patients with AN Purging (AN-P) than in AN-R59-61. In 
2004, the group of Tanaka replicated their findings in a later study 
which included a third subgroup of AN, a subgroup that required 
emergency hospitalization; in this group the patients were unable to 
eat and had an extreme loss of weight. It showed that the emergency 
group had higher plasma levels of ghrelin than AN-P, and that AN-P 
still had levels greater than the AN-R levels. The three groups expe-
rienced a decrease in their plasma levels of ghrelin after treatment, 
but patients with AN-P still kept the plasma levels of ghrelin higher 
than the control group at the end of rehabilitation62. In 2005 Troisi 
et al., found higher levels of ghrelin during fasting in AN-R patients 
when compared to the AN-P patients63. However, the Troisi group 
compared data between patients with AN-P and BN, which probably 
had a higher BMI, which may explain the difference between the 
results of the two studies. There seems to be a relationship between 
ghrelin concentrations and patients with the compulsive/purging 
subtype for both AN (AN-P) and for BN59-61. However, this finding 
has still not reached a consensus, Monteleone et al. 200847 found 
no significant difference in the concentration of plasma ghrelin 
when fasting in groups with AN-R and AN-P. One explanation for 
these conflicting results is the method used to measure ghrelin and 
how it was performed, the preference for using plasma or serum 
can affect the levels obtained in different studies. The Monteleone 
study has confirmed this hypothesis; the study in 2008 obtained the 
result by screening for ghrelin plasma by way of the ELISA method 
(enzyme-linked immunosorbent assay). Whereas in 201064, in or-
der to study patients with BN, they used the same test used by the 
group of Tanaka in 2003: the RIA (Radioimmunoassay) method and 
observed similar results, higher levels of ghrelin in these patients as 
compared to controls.
Tanaka et al. 200254 and Kojima et al. 200565, also observed eleva-
ted levels of fasting ghrelin in patients with BN. In addition, Tanaka 
in 2002 noted that ghrelin levels were negatively correlated with BMI 
and body fat percentage in both BN, as in the control group54. On 
the other hand, Nakazato et al. in 2004 found no significant differ-
ence between the levels of ghrelin plasma in patients with BN and 
the control group66. One possible explanation for this would be that 
Nakazato et al. 2004 measured ghrelin levels in the serum randomly 
Figure 1. Ghrelin in its non-active form (desacyl ghrelin) being transformed 
into its active form (acyl ghrelin) by the enzyme ghrelin O-acyltransferase 
(GOAT). Adapted from Sato et al. 201280.
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Ghrelin in EDs
The role of ghrelin has been extensively investigated in the etiology 
of obesity and contrary to what was expected, plasma levels seem 
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between 11:00 am-12: 00 pm (postprandially), unlike Tanaka et al. 
2002 who measured when fasting. When Kojima in 2005 measured 
the pre-and postprandial ghrelin, it was noted that the decrease in 
postprandial ghrelin was significantly attenuated in women with BN 
compared to the control group66,67, generating a possible delay in the 
reduction of the hunger sensation in these patients.
Patients with BED tend to show a decrease in ghrelin when 
fasting53,63,68 and a lower postprandial decline compared to the obese 
control group68. This decrease in ghrelin does not seem to reduce the 
propensity to gain weight in BED patients. Low ghrelin levels were 
also found in obese patients and seem to be more related to a sub-
regulation of the release of ghrelin in response to excess weight and a 
lower postprandial decline, possibly acting to maintain the hunger21.
A meta-analysis in 2009 found plasma concentrations in fasting 
and postprandial appetite hormones (gut hormones) in patients with 
AN, BN subtypes. It observed that in 8 studies analyzed, seven found 
elevated levels of plasma ghrelin in all diagnoses, with the exception 
of a single study69.
In conclusion, the studies suggest that the changes found in 
ghrelin may be more related to the behavior of the binging and 
purging60. However, for the time being, it is still not clear as per 
whether ghrelin fundamentally participates as an important factor 
in the etiology of the EDs70.
Ghrelin and the genes
The human ghrelin gene (GHLR, Gene ID: 51738)71 which encodes 
ghrelin is located in the short arm of the chromosome 3 (3p25-26)33. 
Initially it was thought that it would have 4 exons (coding part of the 
gene), but subsequent studies have identified a number of additional 
exons in humans72. The precursor to ghrelin, the pre-proghrelin, is 
formed in the post-transcriptional process of GHLR, it consists of 
518 pb encoded in a sequence of 117 amino acids, distributed over 23 
amino acids of the signal peptide and 94 amino acids of pro-ghrelin, 
which include 28 amino acids of the mature ghrelin and over 66 
additional amino acids73, which include 23 of obestatin (a hormone 
with the antagonistic characteristics of ghrelin, which suppresses 
appetite and stomach activity)74. Therefore, ghrelin and obestatin 
are encoded by the same precursor gene (Figure 2).
The gene of the receptor (GHS-R, Gene ID: 2693)71 was also lo-
cated in the chromosome 3 (3q-26-31)31. The gene consists of two ex-
ons separated by one intron (non-coding part of the gene) (Figu re 3). 
The exon 1 encodes the I-V transmembrane regions and exon 2 
encodes the regions VI and VII75. The GHS-R gene encodes two 
types of mRNA: GHS-R1a and GHS-R1b73. The GHS-R 1a contains 
all 7 transmembrane regions and possess a high affinity with ghrelin, 
while the physiological role of GHS-R1b is not yet entirely clear76.
Figure 2. The human ghrelin gene (GHLR), also called the pre-proghrelin gene and its products. The upper boxes represent the exons, while the numbers 
at the bottom represent the amino acids. Adapted from Liu et al. 201170.
Figure 3. The growth hormone secretagogue receptor gene (GHS-R) and single nucleotide polymorphisms (SNPs) that are most researched in this gene, 
accompanied by their identification numbers. Adapted from Liu et al. 201170.
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The gene of GOAT (MBOAT4; Gene ID: 619373)71 is located in 
the chromosome 8 (8p12) and is expressed mainly in the stomach, in 
the pancreas and in lower concentrations in the bones77,78. This gene 
represents a new candidate gene in genetic research for investigating 
complex phenotypes70 (Figure 4).
In table 2 below, you can see some studies that investigated single 
nucleotide polymorphisms (SNPs) in the ghrelin gene, in indivi duals 
with a diagnosis of an ED. It is noticeable that the studies were still 
inconclusive when the GHRL gene is investigated, these studies 
show different positive and negative associations with different EDs 
diagnoses73,81,82,84,86. However, when they analyzed the genes of the 
GHS-R and of the GOAT some studies have found a positive associa-
tion between polymorphisms and the EDs79. In this sense, only two 
studies have found a positive association between polymorphisms in 
the GHS-R and in the GOAT with BN and AN respectively, which is 
that of Miyasaka et al. 200683 and Muller et al. 201085.
Figure 4.  The enzyme ghrelin O-acyltransferase gene (GOAT) and single nucleotide polymorphisms (SNPs) that are most researched in this chromosome, 
accompanied by their identification numbers. Adapted from Liu et al. 201170.
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Table 1. Studies of ghrelin plasma in differents EDs diagnoses, ordered by month and year of publication
Authors and 
year
Diagnoses 
studied
Hypotheses/
Objectives
Sample Age years
(mean ± SD)
BMI kg/
score
(mean ± SD)
Measurement 
ghrelin
Collection 
of the blood 
sample
Main analyzes 
used statistics
Results
Ariyasu et 
al. 200148
AN and GP To estimate the 
plasma ghrelin in 
humans, ghrelin -LI 
fasting and after 
the meals
N RIA Overnight 
fasting plasma
Student’s 
t-test, linear 
regression 
analysis
The concentration 
of ghrelin was 
higher in AN, 
found a negative 
correlation between 
ghrelin levels and 
BMI compared to 
female CO
33 GP 68,0 ± 4,0 23,3 ± 2,8
31 AN 25,0 ± 1,0 DNS
Control Group
61 CO (35 
female)
26,0 ± 
1,0 (DNS 
female)
20,7 ± 0,3 
(20,4 ± 0,4 
female)
Otto et al. 
200146
AN Investigate the 
involvement of 
ghrelin in the 
pathogenesis 
of EDs, analyze 
circulating levels 
of ghrelin and 
its possible 
correlations with 
clinical parameters 
before and after 
weight gain
N RIA Overnight 
fasting plasma
DNS The concentration 
of plasma ghrelin 
was higher in 
AN, after partial 
improvement, there 
was a decrease in 
circulating ghrelin 
(25%). Negative 
correlation with 
Delta BMI
36 AN 25,0 ± 1,2 15,2 ± 0,2
Control Group
24 CO 31,0 ± 1,4 22,9 ± 0,4
Shiiya et al. 
200237
OB, AN and 
DM2
Research on 
ghrelin in 
metabolic balance, 
measurement of 
plasma ghrelin 
responses in 
plasma ghrelin in 
CO and DM2 and 
investigation of 24 
hours of circulating 
ghrelin profile
N RIA Fasting 
plasma and 
postprandial 
(0, 3, 5, 10, 15, 
30, 60 and 120 
min)
ANOVA, post 
hoc Fisher’s 
test, linear 
regression 
analysis
The concentration 
of plasma ghrelin 
was high in the 
AN, and low in BN, 
it was negatively 
correlated with BMI
17 AN 22,2 ± 2,3 14,2 ± 0,5 
11 OB 35,1 ± 3,7 30,4 ±1,2
42 DM2 58,5 ±1,6 DNS
Control Group
28 CO 30,4 ± 4,1 22,7 ± 0,4
Tanaka et al. 
200254
BN Concentration of 
plasma ghrelin 
fasting will be 
increased in 
the BN or show 
some specificity 
regarding the 
pathology
N RIA Overnight 
fasting plasma
Student’s 
t-test, linear 
regression 
analysis
The concentration 
of ghrelin was 
greater in BN. 
Ghrelin fasting 
was negatively 
correlated with BMI 
and% body fat
15 BN 23,3 ± 5,3 20,0 ± 2,9
Control Group
11 CO 24,0 ± 1,9 21,1 ± 1,2
continuation
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Authors and 
year
Diagnoses 
studied
Hypotheses/
Objectives
Sample Age years
(mean ± SD)
BMI kg/
score
(mean ± SD)
Measurement 
ghrelin
Collection 
of the blood 
sample
Main analyzes 
used statistics
Results
Tolle et al. 
200351
AN Measuring plasma 
levels of ghrelin in 
the AN before and 
after renutrition in 
women CT and CO
N RIA Fasting 
plasma and 
postprandial 
(hours: 800, 
1200, 1600, 
2000, 2400 and 
400 h) 
ANOVA, t-test High plasma levels 
of ghrelin in the AN, 
which remained 
high throughout the 
day and decreased 
after renutrition. 
The CT group had 
intermediate levels 
of ghrelin
9 AN 17,2 ± 0,9 14,6 ± 0,4
7 CT 23,3 ± 3,1 15,7 ± 0,4
Control Group
10 CO 23,2 ± 1,1 21,5 ± 0,7
Tanaka et al. 
2003a59
AN
BN
The presence 
and frequency of 
purging behaviors 
can influence the 
levels of ghrelin
N RIA Overnight 
fasting plasma
Linear 
regression 
analysis, 
ANOVA, post-
hoc Fisher’s 
test
Mean plasma 
ghrelin was higher 
in the AN-R, AN-P 
and BN-P, was 
significantly higher 
in AN-P than AN- R. 
Ghrelin fasting 
was negatively 
correlated with BMI 
and % body fat
21 AN-R 21,8 ± 8,9 13,9 ± 1,9
19 AN-P 24,6 ± 5,5 14,4 ± 2,1
18 BN-P 22,7 ± 5,0 20,0 ± 2,1
13 BN-NP 22,7 ± 6,5 21,2 ± 3,9
Control Group
15 CO 22,1 ± 3,4 21,4 ± 11,0
Nedvidkova 
et al. 200345
AN Study the response 
of plasma ghrelin, 
to food intake, 
meal volume and 
nutritional value
N RIA Fasting 
plasma and 
postprandial 
(30, 60, 90, 120 
min)
Unpaired t-test, 
Mann-Whitney 
rank Test, 
correlations 
Spearman’s, 
ANOVA, 
Dunnet´s test
The concentration 
of plasma ghrelin 
was two times 
higher in the AN, 
and was negatively 
correlated with % 
body fat. There was 
no change in the 
concentration of 
ghrelin in the AN 
after 2 h meal
5 AN 24,3 ± 2,6 15,2 ± 1,5
Control Group
6 CO 22,9 ± 4,7 21,6 ± 1,2
Tanaka et al. 
2003b60
AN Measure plasma 
concentrations of 
ghrelin between 
subtypes of AN
N RIA Overnight 
fasting plasma
Linear 
regression 
analysis, 
ANOVA, post-
hoc Scheffe’s 
test
The plasma levels 
of ghrelin were 
higher in AN-R and 
AN-P. Ghrelin was 
even higher in the 
AN-P as compared 
to the AN-R. 
Ghrelin fasting 
was negatively 
correlated with BMI 
in AN
19 AN-R 20,1 ± 4,9 13,6 ± 1,5
20 AN-P 21,9 ± 4,7 13,7 ± 1,9
Control Group
11 CO 21,0 ± 1,9 21,4 ± 1,2
Monteleone 
et al. 200352
BN Study of ghrelin 
and leptin 
responses meals in 
BN and CO
N RIA Fasting 
plasma and 
postprandial (0, 
45, 60, 90, 120 
and 180 min)
ANOVA, 2-way 
ANOVA with 
repeated 
measures 
e post-hoc 
Turkey´s, 
correlation 
Pearson´s
Found no difference 
between groups 
in fasting ghrelin. 
Noted that the 
postprandial ghrelin 
remained increased 
in the BN (90, 
120 and 180 min). 
Ghrelin fasting 
was negatively 
correlated with 
body fat
9 BN-P 24,2 ± 2,3 21,7 ± 3,4
Control Group
12 CO 24,5 ± 2,6 21,5 ± 1,8
Tanaka et al. 
2003c61
AN The differences 
in eating behavior 
can influence the 
secretion of ghrelin 
and insulin in AN
N RIA Fasting 
plasma and 
postprandial 
(0, 30, 60, 120 
and 180 min)
ANOVA, post-
hoc Scheffe’s 
test, Kruskal–
Wallis, chi-
square statistic
The baseline ghrelin 
in AN-R and AN-P 
was significantly 
higher compared 
with CO. In the 
AN-P was found 
delayed recovery 
levels of ghrelin 
postprandially (120 
and 180 min)
11 AN-R 18,5 ± 1,4 13,3 ± 0,4
9 AN-P 20,9 ± 1,4 13,8 ± 0,5
Control Group
10 CO 21,0 ± 0,6 21,4 ± 0,4
continuation
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Authors and 
year
Diagnoses 
studied
Hypotheses/
Objectives
Sample Age years
(mean ± SD)
BMI kg/
score
(mean ± SD)
Measurement 
ghrelin
Collection 
of the blood 
sample
Main analyzes 
used statistics
Results
Soriano-
Guillen et al. 
200441
OBCH, AD 
and AN
To investigate the 
role of ghrelin in 
the EDS analysis 
of baseline ghrelin 
level in OBCH and 
AN and the weight 
loss effect
N RIA Overnight 
fasting plasma
Student´s t 
test, ANOVA 
with repeated 
measures, 
post-hoc 
Scheffe’s test, 
correlation 
analysis
Ghrelin levels were 
decreased in OBCH 
and not normalized 
after weight 
reduction. Also 
found increased 
levels in AN
26 OBCH 8,0 ± 1,3 SD 4,4 ± 1,8
16 AN 17,0 ± 1,6 SD -2,2 ± 
0,4
Control Group
21 CH 6,3 ± 3,0 SD 0,1 ± 1,0
20 AD 17,2 ± 0,4 SD 0,3 ± 0,8
Misra et al. 
200449
AN Ghrelin values may 
be higher in AN 
than in healthy 
adolescents
N RIA Overnight 
fasting plasma
Student´s 
t-test, 
Wilcoxon’s 
test, chi-square 
statistic
Ghrelin levels 
were higher 
and decreased 
postprandially 
ghrelin was also 
high in AN-R
19 AN-R 16,1 ± 1,1 16,9 ± 1,6
Control Group
20 CO 15,4 ± 1,8 21,8 ± 3,7
Nakazato et 
al. 200466
BN Determination 
of serum ghrelin 
levels and compare 
with the BDNF 
reported in a 
previous article
N EIA Postprandial 
(11:00-12:00 
am)
Student’s t-test, 
Mann-Whitney, 
correlation 
Pearson’s
There was 
no significant 
correlation between 
the levels of ghrelin 
and BDNF
18 BN (BN-P 
e BN- NP)
21,6 ± 4,0 20,4 ± 2,1
Control Group
21 CO 21,4 ± 1,7 20,0 ± 1,5
Tanaka et al. 
200462
AN Measuring ghrelin 
and GH in AN 
during treatment 
to evaluate the 
effect of nutritional 
rehabilitation of 
these substances 
in
N RIA Fasting plasma Linear 
regression 
analysis, 
ANOVA, post-
hoc Sheffés, 
Kruskal-Wallis, 
chi-square 
statistic
The fasting ghrelin 
was found too high 
in AN -E group, 
and the high in 
AN-P and AN-R 
before treatment. 
It remained high 
in AN-R during 
the treatment and 
after the treatment 
it maintained 
high only in the 
AN-P group. The 
concentration 
of ghrelin was 
negatively 
correlated with BMI 
before and during 
treatment
7 AN-E 18,1 ± 1,2 11,1 ± 0,3
14 AN-R 18,4 ± 1,3 13,1 ± 0,2
13 AN-P 25,0 ± 1,3 14,5 ± 0,3
Control Group
9 CO 21,5 ± 0,9 21,5 ± 0,4
Kojima et al. 
200565
BN To investigate the 
changes in plasma 
ghrelin and PYY 
postprandial after 
the meal in the BN 
and CO
N RIA Overnight 
fasting 
plasma and 
postprandial 
(0, 30, 60, 120 
and 180 min)
Student’s 
t-test, ANOVA 
with repeated 
measures, 
correlation 
Pearson’s
Concentration of 
plasma ghrelin was 
high in the BN and 
remained high after 
the meal
10 BN-P 24,7 ± 1,5 20,0 ± 0,6
Control Group
12 CO 24,8 ± 0,8 20,2 ± 0,5
Monteleone 
et al. 200553
BN, BED and 
OB
To investigate the 
changes of plasma 
ghrelin in EDs
N RIA Overnight 
fasting plasma
Kruskal-Wallis, 
Mann-Whitney, 
correlations 
Spearman’s
Plasma ghrelin 
reduced in BED 
and OB, but 
found no changes 
in BN. Ghrelin 
was negatively 
correlated with 
body weight, BMI 
and body fat in all 
sample
13 BED NO 26,9 ± 8,0 25,8 ± 2,5
34 BED OB 33,6 ± 9,1 39,8 ± 4,9
56 BN-P 23,4 ± 4,3 21,9 ± 3,8
Control Group
28 OB 38,4 ± 14,1 38,1 ± 6,3
51 CO 22,6 ± 3,1 21,7 ± 2,3
Monteleone 
et al. 200567
BN Investigate the 
total PYY and 
ghrelin responses 
after a high fat 
meal in BN and CO
N RIA Fasting 
plasma and 
postprandial (0, 
45, 60, 90, 120 
and 180 min)
ANOVA, 2-way 
ANOVA with 
repeated 
measures, post 
hoc Turkey, 
multiple 
regression 
analysis
There was no 
difference in the 
concentration of 
ghrelin fasting. The 
postprandial ghrelin 
remained higher 
in BN
9 BN-P 24,5 ± 2,6 21,5 ± 1,8
Control Group
10 CO 24,2 ± 3,9 21,7 ± 3,4
continuation
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Authors and 
year
Diagnoses 
studied
Hypotheses/
Objectives
Sample Age years
(mean ± SD)
BMI kg/
score
(mean ± SD)
Measurement 
ghrelin
Collection 
of the blood 
sample
Main analyzes 
used statistics
Results
Stock et al. 
200539
AN and OB PYY may be higher 
in AN and the 
response of PYY, 
ghrelin, GIP and 
satiety to mixed 
meals can be 
impaired in AN and 
obesity
N RIA Fasting 
plasma and 
postprandial 
(15, 60, 90, 
120, 180 and 
240 min)
ANOVA, post-
hoc Bonferroni, 
correlation, 
Wald test, 
correlation 
Pearson’s
Ghrelin was found 
lower in obesity, 
with respect to 
CO and AN. The 
response of ghrelin 
in each group 
showed a significant 
difference over time
10 AN 16,5 ± 0,4 16,3 ± 0,4
10 OB 14,2 ± 0,3 34,4 ± 2,0
Control Group
10 CO 14,8 ± 0,3 20,2 ± 0,4
Geliebter et 
al. 200568
BED and 
SBED
BED patients 
have higher levels 
of postprandial 
ghrelin, as a 
gastric emptying 
rate slower and 
less that the 
postprandial CCK 
than CO
N RIA Overnight 
fasting 
plasma and 
postprandial 
(-15, 0, 5, 15, 
30, 60, 120 
min)
GLM, post-hoc 
Turkey´s
Plasma ghrelin was 
smaller and had a 
smaller decline after 
the meal in the BED 
compared to CO
11 BED 29,0 ± 8,4 36,6 ± 6,2
14 SBED 28,6 ± 6,7 35,9 ± 5,3
Control Group
12 OB 33,1 ± 8,7 35,3 ± 5,5
Otto et al. 
200558
AN To investigate 
the suppression 
of postprandial 
ghrelin in AN 
during weight gain
N RIA Overnight 
fasting 
plasma and 
postprandial 
(20 and 60 min)
ANOVA of 
repeated 
measurement, 
Wilcoxon test
Increased levels 
of ghrelin in AN 
fasting and there 
was a significant 
decrease after the 
weight gain 
20 AN 25,6 ± 1,0 15,1 ± 0,3
Control Group
6 CO 28,8 ± 1,0 21,1 ± 0,7
Troisi et al.  
200563
AN, BN and 
BED
To investigate 
the relationship 
between plasma 
ghrelin, cortisol, 
thyroid hormones 
and dietary 
patterns of AN, BN 
and BED. Analyzing 
the groups To 
by the criterion 
of bingeing and 
purging
N RIA Overnight 
fasting plasma
ANOVA, 
Student’s 
t-test, post-
hoc Sheffé, 
Stepwise’s 
regression
High plasma 
concentrations 
of ghrelin in the 
AN, BN and BED 
were found. EDs 
concentrations 
of plasma ghrelin 
was negatively 
correlated with 
BMI. Positive 
correlation between 
the concentrations 
of ghrelin and 
disordered eating 
behavior.
13 AN-R 26,6 ± 6,7 15,9 ± 2,3
16 BN (AN-P 
e BN-P)
29,2 ± 11,4 26,0 ± 7,5
21 BED (BN-
NP e BED)
38,0 ± 11,9 33,0 ± 7,8
Control Group
23 CO 25,5 ± 3,2 21,24 ± 1,8
Janas-Kozik 
et al. 200755
AN To investigate the 
involvement of the 
AN dysfunction 
during treatment of 
ghrelin
N RIA Fasting plasma Student’s t-test 
and Spearman’s 
correlation 
The concentration 
of ghrelin was high 
in the AN-R and not 
fully stabilized after 
treatment. Negative 
correlation with 
total plasma ghrelin 
and BMI in AN-R 
after treatment
30 AN-R 18,0 ± 2,0 15,1 ± 1,4
Control Group
20 CO 18,5 ± 0,5 21,4 ± 2,1
Nakahara et 
al. 200756
AN Measure ghrelin, 
PYY3-36, glucose 
and insulin after a 
meal to evaluate 
the effect of 
nutritional status 
in AN during 
hospitalization
N RIA Overnight 
fasting 
plasma and 
postprandial 
(0, 30, 60, 120 
and 180 min)
ANOVA and 
post-hoc 
Sheffé, 2-way 
ANOVA with 
repeated 
measures
Plasma ghrelin 
fasting was 
higher in AN, 
after treatment 
decreased but 
remained higher 
compared to CO
14 AN-R 24,6 ± 6,0 12,4 ± 1,7
Control Group
12 CO 25,7 ± 6,7 22,3 ± 2,2
Monteleone 
et al. 200847
AN and BN Measure 
circulating levels of 
ghrelin/obestatin 
and evaluating its 
relationship with 
anthropometric 
and clinical 
measures in BN, 
AN and CO
N ELISA Overnight 
fasting plasma
Shapiro Wilk 
normality 
test, ANOVA, 
Pearson´s 
correlation
The concentration of 
ghrelin was higher in 
the AN, regardless 
of subtype. No 
difference to the 
BN was found. The 
concentration of 
plasma ghrelin in the 
AN had a positive 
correlation with 
body fat and BMI
21 AN (AN-
R e AN-P)
23,4 ± 7,5 16,6 ± 1,6
21 BN 26,2 ± 7,1 21,4 ± 3,3
Control Group
20 CO 23,6 ± 5,5 21,1 ± 2,2
continuation
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Table 2. Studies of candidate genes for polymorphisms in the ghrelin gene (GHRL), the ghrelin O-acyltransferase (GOAT) and the GH secretagogue receptor 
(GHS-R) in EDs diagnoses
Authors and 
Year
Diagnoses 
studied
Hypotheses Gene Polymorphisms N Control Group Associations Conclusion Country 
of Study
Cellini et al.  
200673
AN and BN To analyze whether 
polymorphisms of 
the ghrelin gene 
which may be 
involved in the 
etiology of the EDs.
GHRL -Gln90Leu,
-Leu72Met,
-Arg51Gln,
-366 AN
-326 BN
-529 AN and 
BN family trios
342 Control 
Subjects
No association 
was found
 Unlikely that these 
polymorphisms are 
related to EDs in the 
European population
Europe
Ando et al. 
200681
AN and BN Is Ghrelin involved 
in the etiology of 
the EDs?
GHRL -Leu72Met,
-3056 T>C 
(rs2075356)
-131 AN-R
-97 AN-P
-108 BN
300 Control 
Subjects
Found in the two 
polymorphisms 
for BN
These polymorphisms 
may be involved in the 
etiology of ED
Japan
Monteleone 
et al. 200682
AN and BN Functional 
variations in the 
ghrelin gene 
may contribute 
to genetic 
susceptibility to 
ED or modulate 
some aspect of 
the phenotype of 
the EDs
GHRL -Arg51Gln,
-Leu72Met
-114 BN
-31 AN-R
-29 AN-P
119 Control 
Subjects
No association 
was found
Suggest that these 
polymorphisms of 
ghrelin should not 
contribute to the 
genetic vulnerability 
for AN or BN
Italy
Miyasaka et 
al.  200683
AN, BN and 
EDNOS
Investigate a new 
polymorphism in 
the GHS-R because 
the polymorphism 
in GHRL-Leu72Met 
was not previously 
detected in 
the Japanese 
population
GHS-R -rs495225 (171C 
to T) 
-96 AN
-116 BN
-16 EDNOS
284 Control 
Subjects
Found for BN This polymorphism 
may be a risk factor 
for BN
Japan
Dardennes et 
al. 200784
AN To analyze whether 
polymorphisms of 
the ghrelin gene 
which may be 
involved in the 
etiology of the EDs.
GHRL -Gln90Leu,
-Leu72Met,
-114 AN-R and 
related
-90 AN-P and 
related
Does not exist Found in the 
AN-P in the 
Leu72Met
Genetic analyses 
with simultaneous 
genetic-biological 
determinants may 
help explain the high 
degree of heritability 
and the standard 
pathophysiological 
description of the EDs
France
Authors and 
year
Diagnoses 
studied
Hypotheses/
Objectives
Sample Age years
(mean ± SD)
BMI kg/
score
(mean ± SD)
Measurement 
ghrelin
Collection 
of the blood 
sample
Main analyzes 
used statistics
Results
Monteleone 
et al. 201064
BN To investigate the 
ghrelin response 
in “misleading” 
feedback on BN 
and CO
N RIA Fasting 
plasma and 
postprandially 
(0, 15, 30, 45, 
90 and 120 
min)
ANOVA, 2-way 
ANOVA with 
repeated 
measures 
and post-hoc 
Turkey’s, 
Pearson’s 
correlation
In BN ghrelin was 
high postprandially. 
The response 
of ghrelin was 
positively correlated 
with the frequency 
of bingeing and 
purging weekly and 
disease duration
6 BN-P DNS DNS
Control Group
7 CO DNS DNS
Terra et al.  
201357
AN Studying levels 
of circulating 
adipocytokines in 
AN and CO
N ELISA Overnight 
fasting plasma
Student’s t-test, 
Pearson’s 
correlation, 
linear 
regression 
analysis
There was no 
difference in the 
concentration of 
ghrelin fasting. 
Negative correlation 
with BMI and the 
plasma ghrelin 
in AN-R after 
treatment.
28 AN-R 27,4 ± 1,4 16,8 ± 0,2
Control Group
33 CO 32,6 ± 1,3 21,8 ± 0,3
AD: adolescents; AN: anorexia nervosa; AN-E: anorexia nervosa with emergent hospitalization; AN-P: anorexia nervosa purging type; AN-R: anorexia nervosa restritive type, ANOVA: analysis of 
variance (one-way); BED: binge eating disorder; BN: bulimia nervosa; BN-P: bulimia nervosa purging type; BN-NP: bulimia nervosa nonpurging type; BNDF: brain-derived neurotrophic factor; BMI: body 
mass index; CCK: cholecystokinin; CH: Childs; CO: controls; CT: constitutionally thin subjects; DM2: diabetes mellitus type 2; DNS: data had not shown; ED: eating disorder; EIA: enzyme immunoassay; 
ELISA: enzyme-linked immunosorbent assay; GH: growth hormone; Ghrelin-LI: ghrelin-like immunoreactivity; GIP: gastric inhibitory polypeptide; GLM: generalized linear model; GP: gastrectomized 
patients; NO: non-obese patients; OB: obese patients without eating disorders; OBCH: obese childs without eating disorders; PYY: peptide YY; RIA: radioimmunoassay; SD: BMI curves above Spanish 
standards; SBED: subthreshold binge eating disorder.
continuation
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Conclusion
In recent years, ghrelin has been an object of study in the EDs, but we 
haven’t had any clear conclusions about its role in these pathologies. 
Genetic research could bring a different perspective and provide a 
new direction for research.
The studies suggest that some polymorphisms in the ghrelin gene, 
mainly in the genes of GHS-R and the GOAT, may be involved in 
the pathogenesis of the EDs and possibly related to the behavior of 
binge eating and purging. However, this is a case of only two studies, 
further work should be conducted with larger samples addressing 
the need to compare the polymorphisms found between the three 
main types of eating disorders (AN, BN and BED) in order for greater 
clarity in the associations.
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